470 related articles for article (PubMed ID: 24923038)
21. New HCV therapies on the horizon.
Vermehren J; Sarrazin C
Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C treatment: an incipient therapeutic revolution.
deLemos AS; Chung RT
Trends Mol Med; 2014 Jun; 20(6):315-21. PubMed ID: 24636306
[TBL] [Abstract][Full Text] [Related]
23. Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).
; Coco B; Caraceni P; Aghemo A; Bitetto D; Bruno R; Ciancio A; Marzioni M; Petta S; Rendina M; Valenti L;
Dig Liver Dis; 2014 Jan; 46(1):18-24. PubMed ID: 24119482
[TBL] [Abstract][Full Text] [Related]
24. Boceprevir, an NS3 protease inhibitor of HCV.
Berman K; Kwo PY
Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
[TBL] [Abstract][Full Text] [Related]
25. Future perspectives: towards interferon-free regimens for HCV.
Gane E
Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
[TBL] [Abstract][Full Text] [Related]
26. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
Sethi N; Tapper EB; Vong A; Sethi S; Rourke M; Afdhal NH
J Viral Hepat; 2015 Dec; 22(12):974-6. PubMed ID: 26010946
[TBL] [Abstract][Full Text] [Related]
27. The role of resistance in HCV treatment.
Vermehren J; Sarrazin C
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):487-503. PubMed ID: 23199507
[TBL] [Abstract][Full Text] [Related]
28. Anemia management in patients with chronic viral hepatitis C.
Hynicka LM; Heil EL
Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
[TBL] [Abstract][Full Text] [Related]
29. Future of hepatitis C therapy: development of direct-acting antivirals.
Dore GJ; Matthews GV; Rockstroh J
Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
[TBL] [Abstract][Full Text] [Related]
30. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
31. Telaprevir: changing the standard of care of chronic hepatitis C.
Rajani AK; Ravindra BK; Dkhar SA
J Postgrad Med; 2013; 59(1):42-7. PubMed ID: 23525057
[TBL] [Abstract][Full Text] [Related]
32. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
Welsch C; Jesudian A; Zeuzem S; Jacobson I
Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
[TBL] [Abstract][Full Text] [Related]
33. Emerging treatments for chronic hepatitis C.
Hayes CN; Chayama K
J Formos Med Assoc; 2015 Mar; 114(3):204-15. PubMed ID: 25300586
[TBL] [Abstract][Full Text] [Related]
34. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Marks KM; Jacobson IM
Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C virus NS3 inhibitors: current and future perspectives.
Salam KA; Akimitsu N
Biomed Res Int; 2013; 2013():467869. PubMed ID: 24282816
[TBL] [Abstract][Full Text] [Related]
36. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.
Welzel TM; Dultz G; Zeuzem S
J Hepatol; 2014 Nov; 61(1 Suppl):S98-S107. PubMed ID: 25443350
[TBL] [Abstract][Full Text] [Related]
37. The role of triple therapy in HCV genotype 1-experienced patients.
Fried MW
Liver Int; 2011 Jan; 31 Suppl 1():58-61. PubMed ID: 21205139
[TBL] [Abstract][Full Text] [Related]
38. New pharmacotherapy for hepatitis C.
Assis DN; Lim JK
Clin Pharmacol Ther; 2012 Sep; 92(3):294-305. PubMed ID: 22850602
[TBL] [Abstract][Full Text] [Related]
39. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
Nelson DR
Liver Int; 2011 Jan; 31 Suppl 1():53-7. PubMed ID: 21205138
[TBL] [Abstract][Full Text] [Related]
40. Understanding the molecular targets for new therapeutical agents in hepatitis c infection.
Vagu C; Sultana C; Ruţă S
Roum Arch Microbiol Immunol; 2013; 72(1):5-24. PubMed ID: 23947011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
